Abstract: In recent years，targeted therapy has made great progress in the field of ovarian cancer，which has changed the treatment model of ovarian cancer. Bevacizumab has a definite effect in the initial treatment and maintenance treatment of high-risk advanced ovarian cancer，and in the treatment of platinum-sensitive recurrent ovarian cancer and platinum-resistant recurrent ovarian cancer. It can be combined with chemotherapy or used alone. Poly ADP-ribose polymerase（PARP）inhibitor is currently the most important type of drugs in targeted therapy for ovarian cancer. It exerts an anti-tumor effect through a "synthetic lethal" effect，which significantly improves the prognosis of patients with ovarian cancer. PARP inhibitor has been recommended as the standard treatment to be used in the maintenance treatment of platinum-sensitive recurrent ovarian cancer and first-line maintenance treatment for newly-treated advanced ovarian cancer. We should strictly grasp the indications of targeted therapy and pay attention to the standard management of the whole process，including pre-treatment evaluation，monitoring during and after treatment and timely management of adverse events，so as to reduce the occurrence of related adverse events and increase the safety of long-term treatment. At the same time，it can also improve the patients' medication compliance，which is also the basis for ensuring the efficacy.

Key words: ovarian cancer, targeted therapy, poly ADP-ribose polymerase inhibitor, anti-angiogenic therapy, bevacizumab

摘要： 近年来靶向治疗在卵巢癌领域取得了较大进展，改变了卵巢癌的治疗模式。贝伐珠单抗在高危晚期卵巢癌的初始治疗和维持治疗中、在铂敏感和铂耐药复发性卵巢癌的治疗中有确切疗效，可与化疗联合，也可单独应用。聚腺苷二磷酸核糖聚合酶（poly ADP-ribose polymerase，PARP）抑制剂是目前卵巢癌靶向治疗中最重要的一类药物，通过“合成致死”效应发挥抗肿瘤作用，显著改善了卵巢癌患者的预后，已作为标准治疗推荐用于初治晚期卵巢癌的一线维持治疗和铂敏感复发性卵巢癌的维持治疗。靶向治疗在严格掌握适应证的同时，应重视规范化的全程管理，包括用药前评估、用药期间和用药后的监测及不良反应的及时处理，以减少和减轻不良反应的发生，增加长期用药安全性，同时也可提高患者的依从性，这也是保障疗效的基础。

关键词: 卵巢癌, 靶向治疗, 聚腺苷二磷酸核糖聚合酶抑制剂, 抗血管生成药物, 贝伐珠单抗